Twist Bioscience Revenue 2017-2021 | TWST

Twist Bioscience annual/quarterly revenue history and growth rate from 2017 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Twist Bioscience revenue for the quarter ending June 30, 2021 was $0.035B, a 65.12% increase year-over-year.
  • Twist Bioscience revenue for the twelve months ending June 30, 2021 was $0.127B, a 72.76% increase year-over-year.
  • Twist Bioscience annual revenue for 2020 was $0.09B, a 65.67% increase from 2019.
  • Twist Bioscience annual revenue for 2019 was $0.054B, a 113.89% increase from 2018.
  • Twist Bioscience annual revenue for 2018 was $0.025B, a 136.16% increase from 2017.
Twist Bioscience Annual Revenue
(Millions of US $)
2020 $90
2019 $54
2018 $25
2017 $11
2016 $2
Twist Bioscience Quarterly Revenue
(Millions of US $)
2021-06-30 $35
2021-03-31 $31
2020-12-31 $28
2020-09-30 $32
2020-06-30 $21
2020-03-31 $19
2019-12-31 $17
2019-09-30 $16
2019-06-30 $14
2019-03-31 $14
2018-12-31 $11
2018-09-30 $8
2018-06-30 $7
2018-03-31 $6
2017-12-31 $4
2017-09-30
2016-09-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $5.526B $0.090B
Twist Bioscience Corporation operates as a biotechnology company. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development and DNA as a digital data storage medium. Twist Bioscience Corporation is headquartered in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29